Study yields promising results for skin infection drug

12/21/2012 | Reuters

The antibiotic oritavancin performed comparably with standard-of-care vancomycin in terms of efficacy, according to findings from a late-stage trial. The drug met the primary endpoint of the study, which was to halt the spread of the infection and to eliminate fever. The drug was tested for the treatment of acute bacterial skin and skin structure infections by gram-positive bacteria, including methicillin-resistant Staphylococcus aureus.

View Full Article in:

Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC